Skip to main content
SpringerLink
Log in

Prognostic factors and COX-2 expression in advanced stage esophageal squamous cell carcinoma

  • Published:
Advances in Therapy Aims and scope Submit manuscript

Abstract

Cyclooxygenase-2 (COX-2) is overexpressed in various types of human malignancies, including squamous cell carcinomas of the esophagus, but its clinicopathologic role in esophageal squamous cell carcinoma (ESCC) remains unclear. The aim of this study was to analyze expression of COX-2 in ESCC and to correlate this expression with clinicopathologic parameters and survival. From 1999 to 2003, endoscopic tissue samples from 110 patients with ESCC were collected for analysis. COX-2 expression was examined through immunohistochemical staining. Clinicopathologic data were analyzed to verify significance. COX-2 expression was detected in 50 of 110 ESCC specimens (45%). COX-2 expression was negative to weak in 73% (COX-2 low) and moderate to strong in 27% (COX-2 high) of tumors. Statistical differences between COX-2 high and COX-2 low were found according to status of the stage (stage IVM1a/IVM1b) (P=.001): cancer antigen (CA) 19-9 (normal/high) (P=.011), CA 12-5 (normal/high) (P=.011), and CA 15-3 (normal/high) (P=.035). Survival was significantly reduced among patients with high COX-2 expression (median overall survival, 3 mo) when compared with the COX-2 low group (median overall survival, 6 mo) (P=.0001). In the univariate analysis, age, body mass index, stage, COX-2, lactate dehydrogenase, CA 12-5, and CA 15-3 were significant factors for survival. With the use of COX regression analysis, only stage (P=.000), COX-2 (P=.000), lactate dehydrogenase (P=.023), and CA 15-3 (P=.002) were independent prognostic factors. Results showed that in patients with ESCC, COX-2 overexpression was significantly correlated with visceral metastases (IVM1b). COX-2 overexpression is an unfavorable prognostic factor in ESCC.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Similar content being viewed by others

References

  1. Nagamatsu M, Mori M, Kuano H, Sugimachi K, Akiyoshi T. Serial histologic investigation of squamous epithelial dysplasia associated with carcinoma of the esophagus.Cancer. 1992; 69: 1094–1098.

    Article  PubMed  CAS  Google Scholar 

  2. Sarbia M, Verreet P, Bittinger F, et al. Basaloid squamous cell carcinoma of the esophagus: diagnosis and prognosis.Cancer. 1997; 79: 1871–1878.

    Article  PubMed  CAS  Google Scholar 

  3. Thun MJ, Namboodiri MM, Calle EE, Flanders WD, Heath CWJ. Aspirin use and risk of fatal cancer.Cancer Res. 1993; 53: 1322–1327.

    PubMed  CAS  Google Scholar 

  4. Pairet M, Engelhardt G. Distinct isoforms (COX-1 and COX-2) of cyclooxygenase: possible physiological and therapeutic implications.Fundam Clin Pharmacol. 1996; 10: 1–17.

    Article  PubMed  CAS  Google Scholar 

  5. William CS, Dubois RN. Prostaglandins endoperoxide synthase: why two isoforms?Am J Physiol. 1996; 270: 803–809.

    Google Scholar 

  6. Chan G, Boyle JO, Yang EK, et al. Cyclooxygenase-2 expression is up-regulated in squamous cell carcinoma of the head and neck.Cancer Res. 1999; 59: 991–994.

    PubMed  CAS  Google Scholar 

  7. Soslow RA, Dannenberg AJ, Rush D, et al. COX-2 is expressed in human pulmonary, colonic, and mammary tumors.Cancer. 2000; 89: 2637–2645.

    Article  PubMed  CAS  Google Scholar 

  8. Ristimaki A, Honkanen N, Jankala H, Sipponen P, Harkönen M. Expression of cyclooxygenase-2 in human gastric carcinoma.Cancer Res. 1997; 57: 1276–1280.

    PubMed  CAS  Google Scholar 

  9. Tucker ON, Dannenberg AJ, Yan EK, et al. Cyclooxygenase-2 expression is up-regulated in human pancreatic cancer.Cancer Res. 1999; 59: 987–990.

    PubMed  CAS  Google Scholar 

  10. Khuri FR, Wu H, Lee JJ, et al. Cyclooxygenase-2 overexpression is a marker of poor prognosis in stage I non-small cell lung cancer.Clin Cancer Res. 2001; 7: 861–867.

    PubMed  CAS  Google Scholar 

  11. Buskens CJ, Van Rees BP, Sivula A, et al. Prognostic significance of elevated cyclooxygenase 2 expression in patients with adenocarcinoma of the esophagus.Gastroenterology. 2002; 122: 1800–1807.

    Article  PubMed  CAS  Google Scholar 

  12. Zimmermann KC, Sarbia M, Weber AA, Borchard F, Gabbert HE, Schror K. Cyclooxygenase-2 expression in human esophageal carcinoma.Cancer Res. 1999; 59: 198–204.

    PubMed  CAS  Google Scholar 

  13. Biramijamel F, Allameh A, Mirbod P, Groene HJ, Koomagi R, Hollstein M. Unusual profile and high prevalence ofp53 mutations in esophageal squamous cell carcinoma from northern Iran.Cancer Res. 2001; 61: 3119–3123.

    Google Scholar 

  14. Kuo K-T, Chow K-C, Wu Y-C, et al. Clinicopathologic significance of cyclooxygenase-2 overexpression in esophageal squamous cell carcinoma.Ann Thorac Surg. 2003; 76: 909–914.

    Article  PubMed  Google Scholar 

  15. Qiao L, Kozoni V, Tsioulias GJ, et al. Selected eicosanoids increase the proliferation rate of human colon carcinoma cells and mouse colonocytes in vivo.Biochim Biophys Acta. 1995; 1258: 234–247.

    Google Scholar 

  16. Ferrandina G, Lauriola L, Distefano MG, et al. Increased cyclooxygenase-2 expression is associated with chemotherapy resistance and poor survival in cervical cancer patients.J Clin Oncol. 2002; 20: 973–981.

    Article  PubMed  CAS  Google Scholar 

  17. Yu HP, Xu SQ, Liu L, et al. Cyclooxygenase-2 expression in squamous dysplasia and squamous cell carcinoma of the esophagus.Cancer Lett. 2003; 198: 193–201.

    Article  PubMed  CAS  Google Scholar 

  18. Kawabe A, Shimada Y, Uchida S, et al. Expression of cyclooxygenase-2 is associated with carcinogenesis of the lower part of thoracic esophageal squamous cell carcinoma andp53 expression.Oncology. 2002; 65: 46–54.

    Article  Google Scholar 

  19. Hida T, Yatabe Y, Achiva H, et al. Increased expression of cyclooxygenase 2 occurs frequently in human lung cancers, specifically in adenocarcinomas.Cancer Res. 1998; 58: 3761–3764.

    PubMed  CAS  Google Scholar 

Download references

Author information

Authors and Affiliations

  1. Oncology Department, Inonu mah.60.yil sitesi, 25.sok. No: 25, Batikent-Ankara, Turkey

    Suleyman Alici MD (Assoc Prof)

  2. Pathology Department, Medical School ofYuzuncuYil University, Van, Turkey

    Serdar Ugras MD (Prof) & Irfan Bayram MD (Assist Prof)

  3. Radiation Oncology Department, Medical School ofYuzuncuYil University, Van, Turkey

    Mustafa Izmirli MD (Assist Prof)

Authors
  1. Suleyman Alici MD
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Serdar Ugras MD
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. Irfan Bayram MD
    View author publications

    You can also search for this author in PubMed Google Scholar

  4. Mustafa Izmirli MD
    View author publications

    You can also search for this author in PubMed Google Scholar

Rights and permissions

Reprints and permissions

About this article

Cite this article

Alici, S., Ugras, S., Bayram, I. et al. Prognostic factors and COX-2 expression in advanced stage esophageal squamous cell carcinoma. Adv Therapy 23, 672–679 (2006). https://doi.org/10.1007/BF02850306

Download citation

  • Issue Date:

  • DOI: https://doi.org/10.1007/BF02850306

Keywords

Search

Navigation